SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain. The super-thin patch – only 200 micrometers thick – was designed to overcome safety issues common in prescription-strength painkillers for chronic pain.

SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain. The super-thin patch – only 200 micrometers thick – was designed to overcome safety issues common in prescription-strength painkillers for chronic pain.

SHANGHAI – Discovering and developing new drugs is hard anywhere in the world but perhaps especially so in China where it is a relatively new pursuit. For those who take on the challenge of bringing new drugs to market, now there is a place to share their woes and wisdom: the New Drug Founder's Club, or NDFC for short.

SHANGHAI – Innovent Biologics Inc., an antibody-focused company based in Suzhou, is betting that the best things will come in pairs. The Chinese biopharma signed its second deal with Adimab LLC, an antibody developer based in Lebanon, N.H., this time for bispecifics. Moreover, this is Innovent's second bispecifics agreement in the span of a week, having also inked a $120 million deal with local start-up, Epimab Biotherapeutics Inc., for its DNA-based approach to bispecifics.

SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) is a biopharma unwilling to leave any stone unturned with its c-Met inhibitor, savolitinib. The Nasdaq-listed, China-based company has 11 clinical trials in 17 different indications for savolitinib.

SHANGHAI – Innovent Biologics Inc., an antibody-focused company based in Suzhou, is betting that the best things will come in pairs.

SHANGHAI – Shenyang Sunshine Pharmaceutical Co. Ltd. (3SBio), a revenue-generating biotech with products in China, has decided to try its hand at the hottest category in immuno-oncology. The company will be responsible for developing three chimeric antigen receptor T cell (CAR T) candidates in Greater China (including Macao and Hong Kong) originally discovered by TNK Therapeutics Inc. (TNK), of San Diego. TNK, a cellular therapy company, is a subsidiary of Nasdaq-listed Sorrento Therapeutics Inc. (SRNE).

SHANGHAI – Shenyang Sunshine Pharmaceutical Co. Ltd. (3SBio), a revenue-generating biotech with products in China, has decided to try its hand at the hottest category in immuno-oncology.

SHANGHAI – Epimab Biotherapeutics Inc., of Shanghai, inked its first licensing deal for its bispecific antibody platform technology to one of China's rising biopharma stars, Innovent Biologics Inc., of Suzhou.